Optimization of a Novel Quinazolinone-Based Series of Transient Receptor Potential A1 (TRPA1) Antagonists Demonstrating Potent in Vivo Activity

  • J Med Chem. 2016 Mar 24;59(6):2794-809. doi: 10.1021/acs.jmedchem.6b00039.
Laurie B Schenkel  1  2 ,  Philip R Olivieri  1  2 ,  Alessandro A Boezio  1  2 ,  Holly L Deak  1  2 ,  Renee Emkey  1  2 ,  Russell F Graceffa  1  2 ,  Hakan Gunaydin  1  2 ,  Angel Guzman-Perez  1  2 ,  Josie H Lee  1  2 ,  Yohannes Teffera  1  2 ,  Weiya Wang  1  2 ,  Beth D Youngblood  1  2 ,  Violeta L Yu  1  2 ,  Maosheng Zhang  1  2 ,  Narender R Gavva  1  2 ,  Sonya G Lehto  1  2 ,  Stephanie Geuns-Meyer  1  2
Affiliations
  • 1. Departments of Medicinal Chemistry, ‡Lead Discovery, §Molecular Structure, and ∥Pharmacokinetics and Drug Metabolism, Amgen, Inc. , 360 Binney Street, Cambridge, Massachusetts 02142, United States.
  • 2. Neuroscience, Amgen, Inc. , One Amgen Center Drive, Thousand Oaks, California 91320, United States.
PMID: 26942860 DOI: 10.1021/acs.jmedchem.6b00039
Abstract

There has been significant interest in developing a transient receptor potential A1 (TRPA1) antagonist for the treatment of pain due to a wealth of data implicating its role in pain pathways. Despite this, identification of a potent small molecule tool possessing pharmacokinetic properties allowing for robust in vivo target coverage has been challenging. Here we describe the optimization of a potent, selective series of quinazolinone-based TRPA1 antagonists. High-throughput screening identified 4, which possessed promising potency and selectivity. A strategy focused on optimizing potency while increasing polarity in order to improve intrinsic clearance culminated with the discovery of purinone 27 (AM-0902), which is a potent, selective antagonist of TRPA1 with pharmacokinetic properties allowing for >30-fold coverage of the rat TRPA1 IC50 in vivo. Compound 27 demonstrated dose-dependent inhibition of AITC-induced flinching in rats, validating its utility as a tool for interrogating the role of TRPA1 in in vivo pain models.

Products